悪性腫瘍患者におけるリンパ球サブセットCD56＋CD16＋Cell，CD56＋Cell，CD16＋Cellの占める割合の意義

概要

論文の詳細を見る
In patients with malignant tumors, it has been said that the antitumor cytotoxic abilities of lymphocytes are activated at an early stage but repressed at an advanced stage. In this study, patients were classified into four groups. The first group is preoperative patients, the second is patients in whom all tumor was removed curatively or has not recurred postoperatively, the third is patients who have inoperable multiple tumors and the fourth is patients in a terminal stage who are suffering from disseminated intravascular coagulation (DIC). T Cells and NK Cells in peripheral blood lymphocytes were investigated in them by FACScan. As a result, T Cells, CD3 + CD4 + Cells, CD3 + CD8 + Cells, CD3 + CD4 + Cells/CD3 + CD8 + Cells did not change significantly but NK Cells did so significantly. CD16 + Cells increased significantly and the ratio of CD56 + Cells/CD16 + Cells declined significantly at the advanced stage and the repression of CD56 receptors was recognized at the advanced stage. And so the ratio of CD56 + Cells/CD16 + Cells shows the anti-tumor immunological ability of a patient with a malignant tumor and the existence of CD56 receptor inhibitors is suggested at the stage. Patients in whom all tumor was removed curatively or no recurrence was recognized postoperatively had the highest ratio of CD56 + CD16 + Cells among the groups. This shows that such patients who are removed curatively and not recurrent have more active NK cells than other groups. In has been shown in vitro or in mouse that in parallel with the activation of NK cells, the expression of CD56 receptors increases, but not in patients with a malignant tumor. In this study, we demonstrate that the expression of lymphocyte CD56 receptors shows activities of NK cells and the ratio CD56 + Cells/CD16 + Cells relates closely to antitumor immunological ability in man. Regarding therapy, not repressing the CD56 receptors and not decreasing the ratio of CD56 + Cells/CD16 + Cells are important and increasing CD56 receptor may be one factor to decrease recurrence.

悪性腫瘍患者におけるリンパ球サブセットCD56＋CD16＋Cell，CD56＋Cell，CD16＋Cellの占める割合の意義

スポンサーリンク

概要

著者

関連論文

スポンサーリンク